Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2711
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLassere, MND-
dc.contributor.authorVAN DER HEIJDE, Desiree-
dc.contributor.authorJohnson, KR-
dc.contributor.authorBoers, M-
dc.contributor.authorEdmonds, J-
dc.date.accessioned2007-11-15T21:03:47Z-
dc.date.available2007-11-15T21:03:47Z-
dc.date.issued2001-
dc.identifier.citationJOURNAL OF RHEUMATOLOGY, 28(4). p. 892-903-
dc.identifier.issn0315-162X-
dc.identifier.urihttp://hdl.handle.net/1942/2711-
dc.description.abstractWe evaluate measurement properties of common rheumatoid arthritis (RA) assessments. Included are a comprehensive literature review and new data on the reliability and smallest detectable difference (SDD) for different classes of these measures. We found that certain common measures such as joint counts, pain, and patient global all had poor reliability and showed large SDD compared to multi-item measures of physical/psychological function or compared to radiographic measures. We discuss the implications of these findings on the use of composite endpoints such as the ACR20 or the EULAR responder index in RA clinical trials, particularly the introduction of misclassification bias that arises from differential measurement error, Finally, we consider generically how the concept of the SDD might or might not relate to the concept of the minimal clinically important difference.-
dc.language.isoen-
dc.publisherJ RHEUMATOL PUBL CO-
dc.subject.otherminimal clinically important difference; reliability; randomized controlled trials; articular assessment; health status; radiographs-
dc.titleReliability of measures of disease activity and disease damage in rheumatoid arthritis: Implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials-
dc.typeJournal Contribution-
dc.identifier.epage903-
dc.identifier.issue4-
dc.identifier.spage892-
dc.identifier.volume28-
local.format.pages12-
local.bibliographicCitation.jcatA1-
dc.description.notesSt George Hosp, Dept Rheumatol, Sydney, NSW, Australia. Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands. Limburgs Univ Ctr, Diepenbeek, Belgium. US FDA, CDER, Rockville, MD 20857 USA. VU Univ Hosp, Dept Clin Epidemiol, Amsterdam, Netherlands.Lassere, MND, St George Hosp, Dept Rheumatol, Kogarah, NSW 2217, Australia.-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.isi000167808600041-
dc.identifier.urlhttp://jrheum.com/abstracts/abstracts01/892.html-
item.fullcitationLassere, MND; VAN DER HEIJDE, Desiree; Johnson, KR; Boers, M & Edmonds, J (2001) Reliability of measures of disease activity and disease damage in rheumatoid arthritis: Implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. In: JOURNAL OF RHEUMATOLOGY, 28(4). p. 892-903.-
item.validationecoom 2002-
item.contributorLassere, MND-
item.contributorVAN DER HEIJDE, Desiree-
item.contributorJohnson, KR-
item.contributorBoers, M-
item.contributorEdmonds, J-
item.accessRightsClosed Access-
item.fulltextNo Fulltext-
crisitem.journal.issn0315-162X-
crisitem.journal.eissn1499-2752-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.